These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28088457)

  • 41. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.
    Peek LJ; Brey RN; Middaugh CR
    J Pharm Sci; 2007 Jan; 96(1):44-60. PubMed ID: 16998874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Miniaturized approach for excipient selection during the development of oral solid dosage form.
    Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
    J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanoparticulate Impurities Isolated from Pharmaceutical-Grade Sucrose Are a Potential Threat to Protein Stability.
    Weinbuch D; Ruigrok M; Jiskoot W; Hawe A
    Pharm Res; 2017 Dec; 34(12):2910-2921. PubMed ID: 29067591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
    Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies for improved stability of Peste des Petits Ruminants Vaccine.
    Silva AC; Carrondo MJ; Alves PM
    Vaccine; 2011 Jul; 29(31):4983-91. PubMed ID: 21570436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preformulation studies of l-glutathione: physicochemical properties, degradation kinetics, and
    Liu M; Sharma M; Lu GL; Yin N; Gailani MA; Sreebhavan S; Wen J
    Drug Dev Ind Pharm; 2020 May; 46(5):717-731. PubMed ID: 32249604
    [No Abstract]   [Full Text] [Related]  

  • 48. Development of gel-forming lyophilized formulation with recombinant human thrombin.
    Murányi A; Bartoš P; Tichý E; Lazová J; Pšenková J; Žabka M
    Drug Dev Ind Pharm; 2015; 41(9):1566-73. PubMed ID: 25347143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addition of Amino Acids to Further Stabilize Lyophilized Sucrose-Based Protein Formulations: I. Screening of 15 Amino Acids in Two Model Proteins.
    Forney-Stevens KM; Bogner RH; Pikal MJ
    J Pharm Sci; 2016 Feb; 105(2):697-704. PubMed ID: 26414114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies.
    Majumdar R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liquid formulations for long-term storage of monoclonal IgGs.
    Mueller M; Loh MQ; Tee DH; Yang Y; Jungbauer A
    Appl Biochem Biotechnol; 2013 Feb; 169(4):1431-48. PubMed ID: 23315232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
    Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
    PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One-step continuous extrusion process for the manufacturing of solid dispersions.
    Maniruzzaman M; Nair A; Scoutaris N; Bradley MS; Snowden MJ; Douroumis D
    Int J Pharm; 2015 Dec; 496(1):42-51. PubMed ID: 26403386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody.
    Wakankar AA; Liu J; Vandervelde D; Wang YJ; Shire SJ; Borchardt RT
    J Pharm Sci; 2007 Jul; 96(7):1708-18. PubMed ID: 17238195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved Comparative Signature Diagrams to Evaluate Similarity of Storage Stability Profiles of Different IgG1 mAbs.
    Kim JH; Joshi SB; Esfandiary R; Iyer V; Bishop SM; Volkin DB; Middaugh CR
    J Pharm Sci; 2016 Mar; 105(3):1028-35. PubMed ID: 26886311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential scanning calorimetry to investigate the compatibility of ciprofloxacin hydrochloride with excipients.
    Fathy M; Hassan MA; Mohamed FA
    Pharmazie; 2002 Dec; 57(12):825-8. PubMed ID: 12561245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formulation and Stability of Solutions.
    Akers MJ
    Int J Pharm Compd; 2016; 20(1):41-5. PubMed ID: 27127830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.